Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

References

• Biomarkers Definition Working GroupBiomarkers and surrogate endpoints: preferred definitions and conceptual frameworkClin Pharmacol Ther2001693899511240971
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBHerceptin Adjuvant (HERA) Trial Study TeamTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• EisenMBBrownPODNA arrays for analysis of gene expressionMethods Enzymol199930317920510349646
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• SørlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci U S A2003100188418842312829800
   PubMed Web of Science ®Google Scholar
• van ‘t VeerLJDaiHvan de VijverMJGene expression profiling predicts clinical outcome of breast cancerNature2002415687153053611823860
   PubMed Web of Science ®Google Scholar
• SotiriouCWirapatiPLoiSGene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisJ Natl Cancer Inst200698426227216478745
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• TuttAWangARowlandCRisk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureBMC Cancer2008833919025599
   PubMed Web of Science ®Google Scholar
• MaXJWangZRyanPDA two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell20045660761615193263
   PubMed Web of Science ®Google Scholar
• JansenMPSieuwertsAMLookMPHOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective studyJ Clin Oncol200725666266817308270
   PubMed Web of Science ®Google Scholar
• BogaertsJCardosoFBuyseMTRANSBIG consortiumGene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialNat Clin Pract Oncol200631054055117019432
   PubMedGoogle Scholar
• SparanoJATAILORx: trial assigning individualized options for treatment (Rx)Clin Breast Cancer20067434735017092406
   PubMed Web of Science ®Google Scholar
• RavdinPMSiminoffLADavisGJComputer program to assist in making decisions about adjuvant therapy for women with early breast cancerJ Clin Oncol200119498099111181660
   PubMed Web of Science ®Google Scholar
• WirapatiPSotiriouCKunkelSMeta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Res2008104R6518662380
   PubMed Web of Science ®Google Scholar
• BuyseMLoiSvan’t VeerLTRANSBIG ConsortiumValidation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerJ Natl Cancer Inst200698171183119216954471
   PubMed Web of Science ®Google Scholar
• DesmedtCPietteFLoiSTRANSBIG ConsortiumStrong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesClin Cancer Res200713113207321417545524
   PubMed Web of Science ®Google Scholar
• DaiHvan’t VeerLLambJA cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patientsCancer Res200565104059406615899795
   PubMed Web of Science ®Google Scholar
• YuJXSieuwertsAMZhangYPathway analysis of gene signatures predicting metastasis of node-negative primary breast cancerBMC Cancer2007718217894856
   PubMed Web of Science ®Google Scholar
• TordaiAWangJAndreFEvaluation of biological pathways involved in chemotherapy response in breast cancerBreast Cancer Res2008102R3718445275
   PubMed Web of Science ®Google Scholar
• IwamotoTBianchiniGBooserDGene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancerJ Natl Cancer Inst2011103326427221191116
   PubMed Web of Science ®Google Scholar
• AlexeGDalginGSScanfeldDHigh expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence ratesCancer Res20076722106691067618006808
   PubMed Web of Science ®Google Scholar
• TeschendorffAEMiremadiAPinderSEEllisIOCaldasCAn immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerGenome Biol200788R15717683518
   PubMed Web of Science ®Google Scholar
• SchmidtMBohmDvon TorneCThe humoral immune system has a key prognostic impact in node-negative breast cancerCancer Res200868135405541318593943
   PubMed Web of Science ®Google Scholar
• RodyAHoltrichUPusztaiLT-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersBreast Cancer Res2009112R1519272155
   PubMed Web of Science ®Google Scholar
• ChangJCWootenECTsimelzonAGene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerLancet2003362938136236912907009
   PubMed Web of Science ®Google Scholar
• AyersMSymmansWFStecJGene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorou-racil, doxorubicin, and cyclophosphamide chemotherapy in breast cancerJ Clin Oncol200422122284229315136595
   PubMed Web of Science ®Google Scholar
• GianniLZambettiMClarkKGene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerJ Clin Oncol200523297265727716145055
   PubMed Web of Science ®Google Scholar
• Iwao-KoizumiKMatobaRUenoNPrediction of docetaxel response in human breast cancer by gene expression profilingJ Clin Oncol200523342243115659489
   PubMed Web of Science ®Google Scholar
• HessKRAndersonKSymmansWFPharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancerJ Clin Oncol200624264236424416896004
   PubMed Web of Science ®Google Scholar
• ThuerigenOSchneeweissAToedtGGene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancerJ Clin Oncol200624121839184516622258
   PubMed Web of Science ®Google Scholar
• FarmerPBonnefoiHAnderlePA stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerNat Med2009151687419122658
   PubMed Web of Science ®Google Scholar
• KordeLALusaLMcShaneLGene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerBreast Cancer Res Treat2010119368569920012355
   PubMed Web of Science ®Google Scholar
• KnauerMMookSRutgersEJThe predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerBreast Cancer Res Treat2010120365566120204499
   PubMed Web of Science ®Google Scholar
• MillerTWHennessyBTGonzalez-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJWaleCPrediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyJ Clin Oncol201028111829183420212256
   PubMed Web of Science ®Google Scholar
• CuzickJDowsettMPinedaSPrognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancerJ Clin Oncol201129324273427821990413
   PubMed Web of Science ®Google Scholar
• SangerFCoulsonARA rapid method for determining sequences in DNA by primed synthesis with DNA polymeraseJ Mol Biol19759434414481100841
   PubMed Web of Science ®Google Scholar
• ShyrDLiuQNext generation sequencing in cancer research and clinical applicationBiol Proced Online2013151423406336
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• BanerjiSCibulskisKRangel-EscarenoCSequence analysis of mutations and translocations across breast cancer subtypesNature2012486740340540922722202
   PubMed Web of Science ®Google Scholar
• ShahSPMorinRDKhattraJMutational evolution in a lobular breast tumour profiled at single nucleotide resolutionNature2009461726580981319812674
   PubMed Web of Science ®Google Scholar
• ShahSPRothAGoyaRThe clonal and mutational evolution spectrum of primary triple-negative breast cancersNature2012486740339539922495314
   PubMed Web of Science ®Google Scholar
• Nik-ZainalSVan LooPWedgeDCBreast Cancer Working Group of the International Cancer Genome ConsortiumThe life history of 21 breast cancersCell20121495994100722608083
   PubMed Web of Science ®Google Scholar
• StephensPJTarpeyPSDaviesHOslo Breast Cancer Consortium (OSBREAC)The landscape of cancer genes and mutational processes in breast cancerNature2012486740340040422722201
   PubMed Web of Science ®Google Scholar
• EllisMJDingLShenDWhole-genome analysis informs breast cancer response to aromatase inhibitionNature2012486740335336022722193
   PubMed Web of Science ®Google Scholar
• CurtisCShahSPChinSFThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature2012486740334635222522925
   PubMed Web of Science ®Google Scholar
• BoseRKavuriSMSearlemanACActivating HER2 mutations in HER2 gene amplification negative breast cancerCancer Discov20133222423723220880
   PubMed Web of Science ®Google Scholar
• AndreFBachelotThomas DenisCamponeMarioArray CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01)J Clin Oncol312013 (suppl; abstr 511)
   Web of Science ®Google Scholar
• KimVNHanJSiomiMCBiogenesis of small RNAs in animalsNat Rev Mol Cell Biol200910212613919165215
   PubMed Web of Science ®Google Scholar
• AmbrosVThe functions of animal microRNAsNature2004431700635035515372042
   PubMed Web of Science ®Google Scholar
• IorioMVCroceCMCauses and consequences of microRNA dysregulationCancer J201218321522222647357
   PubMed Web of Science ®Google Scholar
• IorioMVFerracinMLiuCGMicroRNA gene expression deregulation in human breast cancerCancer Res200565167065707016103053
   PubMed Web of Science ®Google Scholar
• IorioMVCasaliniPTagliabueEMénardSCroceCMMicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancerEur J Cancer200844182753275919022662
   PubMed Web of Science ®Google Scholar
• Nana-SinkamSPCroceCMMicroRNAs as therapeutic targets in cancerTransl Res2011157421622521420032
   PubMed Web of Science ®Google Scholar
• VoliniaSGalassoMSanaMEBreast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNAProc Natl Acad Sci U S A201210983024302922315424
   PubMed Web of Science ®Google Scholar
• CascioneLGaspariniPLovatFIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancerPLoS One201382e5591023405235
   PubMed Web of Science ®Google Scholar
• ZhaoJJLinJYangHMicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancerJ Biol Chem200828345310793108618790736
   PubMed Web of Science ®Google Scholar
• Di LevaGGaspariniPPiovanCMicroRNA cluster 221–222 and estrogen receptor alpha interactions in breast cancerJ Natl Cancer Inst20101021070672120388878
   PubMed Web of Science ®Google Scholar
• MillerTEGhoshalKRamaswamyBMicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1J Biol Chem200828344298972990318708351
   PubMed Web of Science ®Google Scholar
• ZhouMLiuZZhaoYMicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expressionJ Biol Chem201028528214962150720460378
   PubMed Web of Science ®Google Scholar
• ZhangHFXuLYLiEMA Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic TargetsCurr Pharm Des EpubJuly192013
   Web of Science ®Google Scholar
• GongCYaoYWangYUpregulation of miR-21 mediates resistance to trastuzumab therapy for breast cancerJ Biol Chem201128621191271913721471222
   PubMed Web of Science ®Google Scholar
• ZhaoRWuJJiaWPlasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapyOnkologie2011341267568022156446
   PubMedGoogle Scholar
• O’TooleSABeithJMMillarEKTherapeutic targets in triple negative breast cancerJ Clin Pathol201366653054223436929
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJRedmondCA randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumorsN Engl J Med198932084794842644532
   PubMed Web of Science ®Google Scholar
• BuzdarAJonatWHowellAAnastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study GroupJ Clin Oncol1996147200020118683230
   PubMed Web of Science ®Google Scholar
• GershanovichMChaudriHACamposDLetrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)Ann Oncol1998966396459681078
   PubMed Web of Science ®Google Scholar
• DombernowskyPSmithIFalksonGLetrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetateJ Clin Oncol19981624534619469328
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
   PubMed Web of Science ®Google Scholar
• BonneterreJThürlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Clin Oncol200018223748375711078487
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYSuperior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer GroupJ Clin Oncol200119102596260611352951
   PubMed Web of Science ®Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJIntergroup Exemestane StudyA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJATAC Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMATAC Trialists’ GroupResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453606215639680
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBaumMATAC/LATTE investigatorsEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol201011121135114121087898
   PubMed Web of Science ®Google Scholar
• The Breast International Group (BIG) 1–98 Collaborative Group; ThürlimannBKeshaviahACoatesASA comparison of letro-zole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• JonatWGnantMBoccardoFEffectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysisLancet Oncol200671299199617138220
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• JakeszRGreilRGnantMAustrian Breast and Colorectal Cancer Study GroupExtended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast Cancer and Colorectal Cancer Study Group Trial 6aJ Natl Cancer Inst200799241845185318073378
   PubMed Web of Science ®Google Scholar
• MamounasEPJeongJHWickerhamDLBenefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trialJ Clin Oncol200826121965197118332472
   PubMed Web of Science ®Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative GroupLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• LuWJXuCPeiZMayhoubASCushmanMFlockhartDAThe tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agentsBreast Cancer Res Treat201213319910921814747
   PubMed Web of Science ®Google Scholar
• LuWJDestaZFlockhartDATamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancerBreast Cancer Res Treat2012131247348121390495
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFQuaresmaAJFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol200220163396340312177099
   PubMed Web of Science ®Google Scholar
• OsborneCKPippenJJonesSEDouble-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trialJ Clin Oncol200220163386339512177098
   PubMed Web of Science ®Google Scholar
• Di LeoAJerusalemGPetruzelkaLResults of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerJ Clin Oncol201028304594460020855825
   PubMed Web of Science ®Google Scholar
• RobertsonJFLindemannJPLlombart-CussacAFulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Res Treat2012136250351123065000
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); DaviesCGodwinJGrayRRelevance of breast cancer hormone receptor and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• ShiLDongBLiZExpression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancerJ Clin Oncol200927213423342919487384
   PubMed Web of Science ®Google Scholar
• HolmCKokMMichalidesRPhosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancerJ Pathol2009217337237918991335
   PubMed Web of Science ®Google Scholar
• SklirisGPNugentZJRowanBGPennerCRWatsonPHMurphyLCA phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancerEndocr Relat Cancer201017358959720418363
   PubMed Web of Science ®Google Scholar
• MurphyLCSeekalluSVWatsonPHClinical significance of estrogen receptor phosphorylationEndocr Relat Cancer2011181R1R1421149515
   PubMed Web of Science ®Google Scholar
• SmithLColemanLJCummingsMExpression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanismsBiochem J2010429228329020462399
   PubMed Web of Science ®Google Scholar
• JärvinenTAPelto-HuikkoMHolliKIsolaJEstrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancerAm J Pathol20001561293510623650
   PubMed Web of Science ®Google Scholar
• SklirisGPLeygueEWatsonPHMurphyLCEstrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic targetJ Steroid Biochem Mol Biol20081091–211018243688
   PubMed Web of Science ®Google Scholar
• LinCYStrömALi KongSInhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancerBreast Cancer Res200792R2517428314
   PubMed Web of Science ®Google Scholar
• SugiuraHToyamaTHaraYExpression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancerJpn J Clin Oncol2007371182082817932113
   PubMed Web of Science ®Google Scholar
• ShaabanAMGreenARKarthikSNuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patientsClin Cancer Res200814165228523518698041
   PubMed Web of Science ®Google Scholar
• ReganMMVialeGMastropasquaMGInternational Breast Cancer Study GroupRe-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assaysJ Natl Cancer Inst200698211571158117077359
   PubMedGoogle Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estro-gen and progesterone receptors in breast cancerJ Clin Oncol201028162784279520404251
   PubMed Web of Science ®Google Scholar
• IwamotoTBooserDValeroVEstrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistryJ Clin Oncol201230772973422291085
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); DaviesCGodwinJGrayRRelevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• AlbaEChaconJILluchAA randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter studyBreast Cancer Res Treat2012136248749323053638
   PubMed Web of Science ®Google Scholar
• TranBBedardPLLuminal-B breast cancer and novel therapeutic targetsBreast Cancer Research201113622122217398
   PubMed Web of Science ®Google Scholar
• RugoHSKeckSReversing hormone resistance: have we found the golden key?J Clin Oncol201230222707270922753913
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• HortobagyiGNPiccartMRugoHEverolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trialCancer Res20117124 Suppl 3105s106s
   Google Scholar
• Piccart-GebhartMJNoguchiSPritchardKIEverolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trialProgram and abstracts of the American Society of Clinical Oncology Annual MeetingJune 1–5, 2012Chicago, IL Abstract 559
   Google Scholar
• US Food Drug AdministrationFDA approves Afinitor for advanced breast cancer7202012 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm
   Google Scholar
• European Medicines AgencyAfinitor (Everolimus): Summary of Product CharacteristicsEuropean Medicines Agency2012 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001038/human_med_000633.jsp&mid=WC0b01ac058001d124Accessed October 10, 2012
   Google Scholar
• HortobagyiGNPiccart-GebhartMRugoHCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2J Clin Oncol312013 (suppl; abstr LBA509)
   Google Scholar
• BaselgaJSemiglazovVvan DamPPhase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJ Clin Oncol200927162630263719380449
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• Lee-HoeflichSTCrockerLYaoEA central role for HER3 in HER2-amplified breast cancer: implications for targeted therapyCancer Res200868145878588718632642
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSFrancoSXFloranceAO’RourkeLMaltzmanJJohnstonSLapatinib plus letrozole as first-Line therapy for HER-2+ hormone receptor-positive metastatic breast cancerOncologist201015212212920156908
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBCLEOPATRA Study GroupPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical OncologyCollege of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• DowsettMProcterMMcCaskill-StevensWDisease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA TrialJ Clin Oncol200927182962296919364966
   PubMed Web of Science ®Google Scholar
• PerezEAReinholzMMHillmanDWHER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialJ Clin Oncol201028284307431520697084
   PubMed Web of Science ®Google Scholar
• ZabagloLStossORüschoffJHERA Trial Study TeamHER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumabAnn Oncol EpubJuly252013
   Web of Science ®Google Scholar
• ShiYHuangWTanYA novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissueDiagn Mol Pathol2009181112119214113
   PubMedGoogle Scholar
• ArribasJBaselgaJPedersenKParra-PalauJLp95HER2 and breast cancerCancer Res20117151515151921343397
   PubMed Web of Science ®Google Scholar
• PedersenKAngeliniPDLaosSA naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasisMol Cell Biol200929123319333119364815
   PubMed Web of Science ®Google Scholar
• SáezRMolinaMARamseyEEp95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerClin Cancer Res200612242443116428482
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcañaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• SperindeJJinXBanerjeeJQuantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsClin Cancer Res201016164226423520664024
   PubMed Web of Science ®Google Scholar
• ScaltritiMChandarlapatySPrudkinLClinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptorClin Cancer Res20101692688269520406840
   PubMed Web of Science ®Google Scholar
• CastiglioniFTagliabueECampiglioMPupaSMBalsariAMénardSRole of exon-16-deleted HER2 in breast carcinomasEndocr Relat Cancer200613122123216601290
   PubMed Web of Science ®Google Scholar
• LalPTanLKChenBCorrelation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomasAm J Clin Pathol2005123454154615743737
   PubMed Web of Science ®Google Scholar
• Gomez PardoPPratABianchiniGPAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancerJ Clin Oncol (Meeting Abstracts)201129 (Abstr 554)
   Google Scholar
• GuoSQSonensheinGEForkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathwayMol Cell Biology2004241986818690
   PubMed Web of Science ®Google Scholar
• CreightonCJFuXHennessyBTProteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerBreast Cancer Res2010123R4020569503
   PubMed Web of Science ®Google Scholar
• LiuLGregerJShiHNovel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXLCancer Res200969176871687819671800
   PubMed Web of Science ®Google Scholar
• XiaWBacusSHegdePA model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProc Natl Acad Sci U S A2006103207795780016682622
   PubMed Web of Science ®Google Scholar
• MontemurroFRossiVCossu RoccaMHormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patientsCancer20121181172621598238
   PubMed Web of Science ®Google Scholar
• AndreFDieciMVDubskyPMolecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerClin Cancer Res2013191283323258741
   PubMed Web of Science ®Google Scholar
• RexerBNArteagaCLIntrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsCrit Rev Oncog201217111622471661
   PubMedGoogle Scholar
• O’ReganROzgurogluMustafaAndreFabricePhase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3)J Clin Oncol312013 (suppl; abstr 505)
   Web of Science ®Google Scholar
• HurvitzSAFabriceABurrisHABOLERO-1: A random-ized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC)J Clin Oncol302012 (suppl; abstr TPS648.)
   Web of Science ®Google Scholar
• WhitesellLLindquistSLHSP90 and the chaperoning of cancerNat Rev Cancer200551076177216175177
   PubMed Web of Science ®Google Scholar
• XuWMimnaughERosserMFSensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90J Biol Chem20012763702270811071886
   PubMed Web of Science ®Google Scholar
• WorkmanPBurrowsFNeckersLRosenNDrugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressAnn N Y Acad Sci2007111320221617513464
   PubMed Web of Science ®Google Scholar
• JhaveriKTaldoneTModiSChiosisGAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersBiochim Biophys Acta20121823374275522062686
   PubMed Web of Science ®Google Scholar
• ModiSStopeckATGordonMSCombination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyJ Clin Oncol200725345410541718048823
   PubMed Web of Science ®Google Scholar
• ModiSStopeckALindenHHSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabClin Cancer Res201117155132513921558407
   PubMed Web of Science ®Google Scholar
• ZagouriFSergentanisTNChrysikosDPapadimitriouCADimopoulosMAPsaltopoulouTHsp90 inhibitors in breast cancer: A systematic reviewBreast201322556957823870456
   PubMed Web of Science ®Google Scholar
• ChandarlapatySScaltritiMAngeliniPInhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthOncogene201029332533419855434
   PubMed Web of Science ®Google Scholar
• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov20098862764419644473
   PubMed Web of Science ®Google Scholar
• BoyaultSDrouetYNavarroCMutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypesBreast Cancer Res Treat20121321293921512767
   PubMed Web of Science ®Google Scholar
• BachmanKEArganiPSamuelsYThe PIK3CA gene is mutated with high frequency in human breast cancersCancer Biol Ther20043877277515254419
   PubMed Web of Science ®Google Scholar
• CarptenJDFaberALHornCA transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature2007448715243944417611497
   PubMed Web of Science ®Google Scholar
• GarciaJMSilvaJMDominguezGAllelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotypeBreast Cancer Res Treat199957323724310617300
   PubMed Web of Science ®Google Scholar
• GarcíaJMSilvaJPeñaCPromoter methylation of the PTEN gene is a common molecular change in breast cancerGenes Chromosomes Cancer200441211712415287024
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• WangLZhangQZhangJPI3K pathway activation results in low efficacy of both trastuzumab and lapatinibBMC Cancer20111124821676217
   PubMed Web of Science ®Google Scholar
• GallardoALermaEEscuinDIncreased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomasBr J Cancer201210681367137322454081
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• MassarwehSOsborneCKCreightonCJTamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionCancer Res200868382683318245484
   PubMed Web of Science ®Google Scholar
• CavazzoniABonelliMAFumarolaCOvercoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesCancer Lett20123231778722484466
   PubMed Web of Science ®Google Scholar
• MillerWRLarionovARenshawLGene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozoleJ Clin Oncol20092791382138719224856
   PubMed Web of Science ®Google Scholar
• MairaSMPecchiSHuangAIdentification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorMol Cancer Ther201211231732822188813
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsPhase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2) Available from http://clinicaltrials.gov/show/NCT01610284. Identifier NCT01610284Accessed November 4, 2013
   Google Scholar
• Novartis PharmaceuticalsA Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi (BELLE-3) Available from http://clinicaltrials.gov/show/NCT01633060. Identifier NCT01633060Accessed November 4, 2013
   Google Scholar
• SauraCBendellJJerusalemGPhase I/II study of BKM120 in combination with trastuzumab in patients with HER2-overexpressing meta-static breast cancer resistant to trastuzumab-containing therapySan Antonio Breast Cancer Conference 2011 [abstract PD09-03]
   Google Scholar
• O’BrienCWallinJJSampathDPredictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical modelsClin Cancer Res201016143670368320453058
   PubMed Web of Science ®Google Scholar
• ChakrabartyASánchezVKubaMGRinehartCArteagaCLFeedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitorsProc Natl Acad Sci U S A201210982718272321368164
   PubMed Web of Science ®Google Scholar
• BrachmannSMHofmannISchnellCSpecific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProc Natl Acad Sci U S A200910652222992230420007781
   PubMed Web of Science ®Google Scholar
• JankuFWhelerJJWestinSNPI3K/AKT/mTOR inhibitors in patients with breast and gynecological malignancies harboring PIK3CA mutationsJ Clin Oncol201230877778222271473
   PubMed Web of Science ®Google Scholar
• JuricDBaselgaJTumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitorsJ Clin Oncol201230876576622271482
   PubMed Web of Science ®Google Scholar
• SerraVScaltritiMPrudkinLPI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene201130222547255721278786
   PubMed Web of Science ®Google Scholar
• TurnerNGroseRFibroblast growth factor signalling: from development to cancerNat Rev Cancer201010211612920094046
   PubMed Web of Science ®Google Scholar
• TenhagenMvan DiestPJIvanovaIAvan der WallEvan der GroepPFibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targetsEndocr Relat Cancer2012194R115R12922508544
   PubMed Web of Science ®Google Scholar
• TurnerNPearsonASharpeRFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerCancer Res20107052085209420179196
   PubMed Web of Science ®Google Scholar
• TurnerNLambrosMBHorlingsHMIntegrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene201029142013202320101236
   PubMed Web of Science ®Google Scholar
• MassabeauCSigal-ZafraniBBelinLThe fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?Breast Cancer Res Treat2012134125926622438050
   PubMed Web of Science ®Google Scholar
• Elbauomy ElsheikhSGreenARLambrosMBFGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysisBreast Cancer Res200792R2317397528
   PubMed Web of Science ®Google Scholar
• SunSJiangYZhangGIncreased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancerJ Surg Oncol2012105877377922006548
   PubMed Web of Science ®Google Scholar
• TomlinsonDKnowlesMASpeirsVMechanisms of FGFR3 actions in endocrine resistant breast cancerInt J Cancer2012130122857286621792889
   PubMed Web of Science ®Google Scholar
• MeijerDSieuwertsAMLookMPFibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancerEndocr Relat Cancer200815110111118310279
   PubMed Web of Science ®Google Scholar
• AndréFBachelotTCamponeMTargeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancerClin Cancer Res201319133693370223658459
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHNeoALTTO Study TeamLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• GianniLBianchiniGValagussaPAdaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere studyCancer Research201272S6S7
   Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMOverall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyJ Clin Oncol201230212585259222689807
   PubMed Web of Science ®Google Scholar